TY  - JOUR

T1  - Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).

JO  - Journal of Clinical Oncology

PY  - 2012/05/20

AU  - Sartor AO

AU  - Heinrich D

AU  - O'Sullivan JM

AU  - Fossa SD

AU  - Chodacki A

AU  - Wiechno PJ

AU  - Logue JP

AU  - Seke M

AU  - Widmark A

AU  - Johannessen DC

AU  - Nilsson S et al

ED  - 

DO  - DOI: 10.1200/jco.2012.30.15_suppl.4551

PB  - American Society of Clinical Oncology (ASCO)

VL  - 30

IS  - 15_suppl

SP  - 4551

EP  - 4551

Y2  - 2025/10/10

ER  -